Nanosuspension Technology for Drug Delivery



The poor water solubility of drugs is major problem for drug formulation. To date, nanoscale systems for drug delivery have gained much interest as a way to improve the solubility problems. The reduction of drug particles into the sub-micron range leads to a significant increase in the dissolution rate and therefore enhances bioavailability. Nanosuspensions are promising candidates that can be used for enhancing the dissolution of poorly water soluble drugs. Nanosuspensions contain submicron colloidal dispersion of pharmaceutical active ingredient particles in a liquid phase stabilized by surfactants. Production of drugs as nanosuspensions has been developed for drug delivery systems as an oral formulation and non-oral administration. This review describes the methods of pharmaceutical nanosuspension production, formulations and pharmaceutical applications in drug delivery as well as the marketed products.


Nanosuspensions, drug delivery, bioavailability, colloid

Full Text:



RH Müller, C Jacobs and O Kayer. Nanosuspensions for the formulation of poorly soluble drugs. In: F Nielloud, G Marti-Mestres (ed). Pharmaceutical emulsion and suspension. New York, Marcel Dekker, 2000, p. 383-407.

RA Nash. Suspensions. In: J Swarbrick, JC Boylan (ed). Encyclopedia of pharmaceutical technology. Second edition vol. 3. New York, Marcel dekker, 2002, p. 2045-3032.

RH Müller and K Peters. Nanosuspensions for the formulation of poorly soluble drug I: Preparation by size reduction technique. Int. J. Pharm. 1998; 160, 229-37.

VB Patravale, AA Date and RM Kulkarni. Nanosuspension: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004; 56, 827-40.

BE Rabinow. Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 2004; 3, 785-96.

T Shah, D Patel, J Hirani and AF Amin. Nanosuspensions as a drug delivery system: A comprehensive review. Drug. Deliv. Tech. 2007; 7, 42-53.

K Peters, S Leitzke, JE Diederichs, K Borner, H Hahn, RH Müller and S Ehlers. Preparation of a clofazamine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 2000; 45, 77-83.

JE Kipp, JCT Wong, MJ Doty and CL Rebbeck. Microprecipitation method for preparing submicron suspensions. US Patent 6,607,784 2003.

Z Zili, S Sfar and H Fessi. Preparation and characterization of poly-ε-carprolactone nanoparticles containing griseofulvin. Int. J. Pharm. 2005; 294, 261-7.

M Trotta, M Gallarete, F Pattarino and S Morel. Emulsions containing partially water-miscible solvents for the preparation of dry nanosuspensions. J. Control. Rel. 2001; 76, 119-28.

X Zhang, Q Xia and N Gu. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug. Dev. Ind. Pharm. 2006; 32, 857-63.

C Jacobs, O Kayser and RH Müller. Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int. J. Pharm. 2001; 214, 3-7.

RH Müller and C Jacobs. Buparvaquone mucoadhesive nanosuspension: preparation, optimization and long-term stability. Int. J. Pharm. 2002; 237, 151-61.

J Möschwitzer, G Achleitner, H Pomper and RH Müller. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 2004; 58, 615-9.

J Hecq, M Deleers, D Fanara, H Vranckx and K Amighi. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 2005; 299, 167-77.

P Kocbek, S Baumgartner and J Kristl. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drug. Int. J. Pharm. 2006; 312, 179-86.

M Trotta, M Gallarate, ME Carlotti and S Morel. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int. J. Pharm. 2003; 254, 235-42.

P Langguth, A Hanafy, D Frenzel, P Grenier, A Nhamias, T Ohlig, G Vergnault and H Spahn-Langguth. Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug. Dev. Ind. Pharm. 2005; 31, 319-29.

JY Chen, LX Yang, LX Zhao and BH Xu. Preparation of oleanolic acid nanosuspension. Chin. Pharm. J. 2006; 41, 924-7.

MP Kumar, YM Rao and S Apte. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr. Nanosci. 2007; 3, 191-4.

D Zhang, T Tan, L Gao, W Zhao and P Wang. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug. Dev. Ind. Pharm. 2007; 33, 569-75.

N Rasenack and BW Müller. Dissolution rate enhancement by in situ micronization of poorly water soluble drugs. Pharm. Res. 2002; 19, 1894-900.

H Steckel, N Rasenack and BW Müller. In situ micronization of disodium cromoglycate for pulmonary delivery. Eur. J. Pharm. Biopharm. 2003; 55, 173-80.

X Chen, TJ Yong, M Sarkari, RO Williams III and KP Johnston. Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002; 242, 3-14.

M Sarkari, J Brown, X Chen, S Swinnea, RO Williams III and KP Johnston. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 2002; 243, 17-31.

CM Keck and RH Müller. Drug nanocrystals of poorly soluble drugs produced by high pressure homoginisation. Eur. J. Pharm. Biopharm. 2006; 62, 3-16.

GG Liversidge and P Conzentino. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995; 125, 309-13.

GG Liversidge, KC Cundy, JF Bishop and DA Czekai. Surface modified drug nanoparticles. US Patent 5, 145, 684, 199.

A Wongmekiat, Y Tozuka, T Oguchi and K Yamamoto. Formation of fine drug particles by co-grinding with cyclodextrin. I. the use of β-cyclodextrin anhydrate and hydrate. Pharm. Res. 2002; 19, 1867-72.

K Itoh, A Pongpeerapat, Y Tozuka, T Oguchi and K Yamamoto. Nanoparticle formation of poorly water soluble drugs from ternary ground mixtures with PVP and SDS. Chem. Pharm. Bull. 2003; 51, 171-4.

P Mura, M Cirri, MT Faucci, JM Ginès-Dorado and GP Bettinetti. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J. Pharm. Biomed. Anal. 2002; 30, 227-37.

P Mura, MT Faucci and GP Bettinetti. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl- β-cyclodextrin. Eur. J. Pharm. Sci. 2001; 13, 187-94.

M Otsuka and Y Matsuda. Effect of co-grinding with various kinds of surfactants on the dissolution behavior of phenytoin. J. Pharm. Sci. 1995; 84, 1434-37.

M Sugimoto, T Okagaki, S Narisawa, Y Koida and K Nakajima. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel co-grinding method using water soluble polymer. Int. J. Pharm. 1998; 160, 11-9.

E Yonemochi, S Kitahara, S Maeda, S Yamamura, T Oguchi and K Yamamoto. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci. 1999; 7, 331-8.

T Watanabe, I Ohno, N Wakiyama, A Kusai and M Senna. Stabilization of amorphous indomethacin by co-grinding in a ternary mixture. Int. J. Pharm. 2002; 241, 103-11.

F Kesisoglou, S Panmai and Y Wu., Nanosizing-Oral formulation development and biopharmaceutical evaluation, Adv. Drug. Deliv. Rev. 2007; 59, 631-44.

E Merisko-Liversidge, GG Liversidge and ER Cooper. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003; 18, 113-20.

O Kayser. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. Int. J. Pharm. 2000; 196, 253-6.

B Rainbow, J Kipp, P Papadopoulos, J Wong, J Glosson, J Gass, C-S Sun, T Wielgos, R White, C Cook, K Barker and K Wood. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetic in the rat. Int. J. Pharm. 2007; 339, 251-60.

JP Remon, GJ Vergote, C Vervaet, I Driessche, S Hoste, S Smedt, J Demeester, RA Jain and S Ruddy. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int. J. Pharm. 2001; 219, 81-7.

S Looareesuwan, JD Chulay, CJ Canfield and DB Hutchinson. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans. R. Soc. Trop. Med. Hyg. 1999; 93, 637-40.

N Schöler, K Krause, O Kayser, RH Müller, K Borner, H Hahn and O Liesenfeld. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 2001; 45, 1771-9.

RH Müller, C Jacobs and O Kayser. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 2001; 47, 3-19.

O Kayser, C Olbrich, V Yardley, AF Kiderlen and SL Croft. Formulation of amphotericin B as nanosuspension for oral administration Int. J. Pharm. 2003; 254, 73-5.

A Hanafy, H Spahn-Langguth, G Vergnault, P Grenier, M T Grozdanis and T Lenhardt. Pharmacokinetic evaluation of oral fenofibrate nanosuspension and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug. Del. Rev. 2007; 59, 419-26.

R Pignatello, C Bucolo, P Ferrara, A Maltese, A Pvleo and G Puglisi. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 2002; 16, 53-61.

MA Kassem, AA Abdel Rahman, MM Ghorab, MB Ahmed and RM Khalil. Nanosuspension as an opthamic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 2007; 340, 126-33.

RH Müller and C Jacobs. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002; 19, 189-94.

N Hernández-Trejo, O Kayser, H Steckel and RH Müller. Characterization of nebulized bupravaquone nanosuspensions-Effect of nebulization technology. J. Drug. Target. 2005; 13, 499-507.

O Kayser. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions:research and applications. Int. J. Pharm. 2001; 214, 83-5.

S Kohno, T Otsubo, E Tanaka, K Maruyama and K Hara. Amphotericin B encapsulated in polyethylene glycol immunoliposomes for infectious diseases. Adv. Drug. Del. Rev. 1997; 24, 325-9.

RH Müller, BHL Böhm and MJ Grau. Nanosuspensions-Formulations for poorly soluble drugs with poor bioavailability/2nd communication: Stability, biopharmaceutical aspects, possible drug forms and registration aspects. Pharm. Ind. 1999; 61, 175-8.

J Shim, HS Kang, W-S Park, S-H Han, J Kim and I-S Chang. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J. Control Rel. 2004; 97, 477-84.

AK Kohli and HO Alpar. Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int. J. Pharm. 2004; 275, 13-7.

Y Yamaguchi, T Nagasawa, N Nakamura, M Takenaga, M Mizoguchi, S-I Kawai, Y Mizushima and R Igarashi. Successful treatment of photo-damaged skin of nano-scale at RA particles using a novel transdermal delivery. J. Control Rel. 2005; 104, 29-40.

X Chen, CY-L Lo, M Sarkari, RO Williams III and KP Johnston. Ketoprofen nanoparticle gels formed by evaporative precipitation into aqueous solution. AIChE J. 2006; 52, 2428-35.

Z-Y She, X Ke, Q-N Ping, B-H Xu and L-L Chen. Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats. Chin. J. Nat. Med. 2007; 5, 50-5.

J-I Jinno, N Kamada, M Miyake, K Yamada, T Mukai, M Odomi, H Toguchi, GG Liversidge, K Higaki and T Kimura. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control Rel. 2006; 111, 56-64.


  • There are currently no refbacks.

Online ISSN: 2228-835X

Last updated: 12 August 2019